Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

New Approval Alert: Bio-Thera/Sandoz’s Biosimilar Bevacizumab Approved in Europe

Jul 30, 2024

On 30 July 2024, Bio-Thera Solutions announced that the European Medicines Agency (EMA) has approved Avzivi® (BAT1706), biosimilar to Genentech’s Avastin® (bevacizumab), for treating various cancers.

In September 2021, Bio-Thera and Sandoz entered an agreement under which Sandoz has the commercialisation rights to Avzivi® in Europe, the US, Canada and other international markets.  Avzivi® was FDA approved in December 2023 and is approved in China as Pobevcy®.

The first bevacizumab biosimilar was approved in the US in September 2017 and in Europe in January 2018.  More recently, in March 2024, Dr Reddy’s launched its Versavo® (bevacizumab) in the UK, five years after its Indian launch.